Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National Health Research Institute and Research Triangle Institute. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.
Frequently asked questions
What sector does Agentix Corp (AGTX) operate in?
Agentix Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Agentix Corp (AGTX) current stock price?
As of the latest data, Agentix Corp stock price is $0.05, with a previous close of $0.07. Agentix Corp lost -$0.02 in the last trading session, representing a -24.29% loss.
What is Agentix Corp (AGTX) current market capitalization?
Agentix Corp market cap is approximately 2.12 million.
What is Agentix Corp (AGTX) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
What is Agentix Corp (AGTX) EBITDA?
Agentix Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -95.50 thousand.
Does Agentix Corp (AGTX) pay dividends?
No. Agentix Corp does not pay a dividend.
What is Agentix Corp (AGTX) beta (volatility) score?
Agentix Corp has a beta of 0.775, indicating lower volatility than the overall market.
